vimarsana.com

Latest Breaking News On - Institutional trading of syros pharmaceuticals - Page 1 : vimarsana.com

Syros Pharmaceuticals (NASDAQ:SYRS) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright restated their buy rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) in a report issued on Wednesday, Benzinga reports. The firm currently has a $15.00 price target on the stock. HC Wainwright also issued estimates for Syros Pharmaceuticals’ Q2 2024 earnings at ($0.73) EPS, Q3 2024 earnings at ($0.74) EPS, Q4 […]

Piper-sandler
Kennedy-capital-management
Syros-pharmaceuticals
News-ratings-for-syros-pharmaceuticals-daily
Syros-pharmaceuticals-stock-performance
Acadian-asset-management
Institutional-trading-of-syros-pharmaceuticals
Opaleye-management-inc
Syros-pharmaceuticals-inc
Vanguard-group-inc
Free-report
Get-free-report

Syros Pharmaceuticals (NASDAQ:SYRS) Given "Buy" Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) in a report published on Wednesday morning, Benzinga reports. HC Wainwright currently has a $15.00 target price on the stock. A number of other research analysts have also recently issued reports on the stock. StockNews.com cut shares of Syros Pharmaceuticals […]

Piper-sandler
Syros-pharmaceuticals
Kennedy-capital-management
Syros-pharmaceuticals-inc
Acadian-asset-management
Vanguard-group-inc
Opaleye-management-inc
News-ratings-for-syros-pharmaceuticals-daily
Syros-pharmaceuticals-stock-down
Institutional-trading-of-syros-pharmaceuticals
Free-report
Pharmaceuticals-stock-down

Syros Pharmaceuticals (NASDAQ:SYRS) Stock Price Passes Below 50 Day Moving Average of $5.94

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Free Report)’s stock price passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $5.94 and traded as low as $5.28. Syros Pharmaceuticals shares last traded at $5.44, with a volume of 199,560 shares traded. Wall Street Analysts […]

Piper-sandler
Syros-pharmaceuticals-inc
Syros-pharmaceuticals-trading
Opaleye-management-inc
News-ratings-for-syros-pharmaceuticals-daily
Syros-pharmaceuticals
Nasdaq
Flagship-pioneering-inc
Institutional-trading-of-syros-pharmaceuticals
Syros-pharmaceuticals-company-profile
Get-free-report
Partners-management

Syros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Sell at StockNews.com

Syros Pharmaceuticals (NASDAQ:SYRS – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday. Syros Pharmaceuticals Price Performance Shares of NASDAQ SYRS traded down $0.10 during mid-day trading on Tuesday, reaching $6.46. The company had a […]

Srinivas-akkaraju
News-ratings-for-syros-pharmaceuticals-daily
Syros-pharmaceuticals-price-performance
Renaissance-technologies
Syros-pharmaceuticals-inc
Blue-owl-capital-holdings
Institutional-trading-of-syros-pharmaceuticals
Syros-pharmaceuticals
Securities-exchange-commission
Bain-capital-life-sciences-investors
Get-free-report
Director-srinivas-akkaraju

Syros Pharmaceuticals (NASDAQ:SYRS) Cut to "Sell" at StockNews.com

Syros Pharmaceuticals (NASDAQ:SYRS) Cut to "Sell" at StockNews.com
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Srinivas-akkaraju
Syros-pharmaceuticals-company-profile
Syros-pharmaceuticals-stock-performance
Syros-pharmaceuticals-inc
News-ratings-for-syros-pharmaceuticals-daily
Vanguard-group-inc
Institutional-trading-of-syros-pharmaceuticals
Syros-pharmaceuticals
Clarius-group
Free-report
Get-free-report
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.